Journey Medical Corp (NASDAQ: DERM) has experienced a decline in its stock price by -7.25 compared to its previous closing price of 3.86. However, the company has seen a fall of -16.94% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-21 that Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript
Is It Worth Investing in Journey Medical Corp (NASDAQ: DERM) Right Now?
Additionally, the 36-month beta value for DERM is 0.75. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”
The public float for DERM is 6.65M and currently, short sellers hold a 2.23% ratio of that float. The average trading volume of DERM on April 19, 2024 was 178.71K shares.
DERM’s Market Performance
DERM stock saw a decrease of -16.94% in the past week, with a monthly decline of -5.54% and a quarterly a decrease of -28.11%. The volatility ratio for the week is 8.79%, and the volatility levels for the last 30 days are 13.59% for Journey Medical Corp (DERM). The simple moving average for the past 20 days is -6.05% for DERM’s stock, with a -2.96% simple moving average for the past 200 days.
Analysts’ Opinion of DERM
Many brokerage firms have already submitted their reports for DERM stocks, with B. Riley Securities repeating the rating for DERM by listing it as a “Buy.” The predicted price for DERM in the upcoming period, according to B. Riley Securities is $14 based on the research report published on December 07, 2021 of the previous year 2021.
DERM Trading at -8.06% from the 50-Day Moving Average
After a stumble in the market that brought DERM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.86% of loss for the given period.
Volatility was left at 13.59%, however, over the last 30 days, the volatility rate increased by 8.79%, as shares sank -6.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.08% lower at present.
During the last 5 trading sessions, DERM fell by -16.94%, which changed the moving average for the period of 200-days by +79.00% in comparison to the 20-day moving average, which settled at $3.80. In addition, Journey Medical Corp saw -37.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DERM starting from ROSENWALD LINDSAY A MD, who purchase 10,000 shares at the price of $3.04 back on Mar 25 ’24. After this action, ROSENWALD LINDSAY A MD now owns 144,245 shares of Journey Medical Corp, valued at $30,400 using the latest closing price.
Smith Justin Adam, the Director of Journey Medical Corp, purchase 30,000 shares at $3.47 during a trade that took place back on Mar 22 ’24, which means that Smith Justin Adam is holding 134,717 shares at $104,100 based on the most recent closing price.
Stock Fundamentals for DERM
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.66 for the gross margin
The net margin for Journey Medical Corp stands at -0.05. The total capital return value is set at -0.06. Equity return is now at value -20.64, with -4.23 for asset returns.
Based on Journey Medical Corp (DERM), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is -1.22.
Currently, EBITDA for the company is 4.92 million with net debt to EBITDA at -3.03. When we switch over and look at the enterprise to sales, we see a ratio of 0.78. The receivables turnover for the company is 5.2for trailing twelve months and the total asset turnover is 1.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In conclusion, Journey Medical Corp (DERM) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
